LIVN logo

LIVN
LivaNova PLC

381
Mkt Cap
$3.49B
Volume
3,216.00
52W High
$71.92
52W Low
$32.48
PE Ratio
-14.19
LIVN Fundamentals
Price
$63.50
Prev Close
$63.79
Open
$63.21
50D MA
$64.88
Beta
0.92
Avg. Volume
888,999.35
EPS (Annual)
-$4.45
P/B
2.89
Rev/Employee
$420,622.12
$3,154.56
Loading...
Loading...
News
all
press releases
Allspring Global Investments Holdings LLC Reduces Stake in LivaNova PLC $LIVN
Allspring Global Investments Holdings LLC lessened its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 8.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 201,832 shares of the company's stock after selling 19,629 sh...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Exchange Traded Concepts LLC Buys New Shares in LivaNova PLC $LIVN
Exchange Traded Concepts LLC purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the...
MarketBeat·3d ago
News Placeholder
Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC $LIVN
Tudor Investment Corp ET AL bought a new stake in LivaNova PLC (NASDAQ:LIVN - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange...
MarketBeat·9d ago
News Placeholder
MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value
MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value PR Newswire VANCOUVER, BC, March 27, 2026 Issued on behalf of...
PR Newswire·11d ago
News Placeholder
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
Zacks·13d ago
News Placeholder
LivaNova to Announce First-Quarter 2026 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The...
Business Wire·13d ago
News Placeholder
LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of "Moderate Buy" from Brokerages
LivaNova PLC (NASDAQ:LIVN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven...
MarketBeat·15d ago
News Placeholder
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000 System for the...
Business Wire·19d ago
News Placeholder
Strength Seen in Tandem Diabetes Care (TNDM): Can Its 9.1% Jump Turn into More Strength?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·20d ago
News Placeholder
Short Interest in LivaNova PLC (NASDAQ:LIVN) Rises By 18.0%
LivaNova PLC (NASDAQ:LIVN - Get Free Report) was the recipient of a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 2,399,324...
MarketBeat·20d ago
<
1
2
...
>

Latest LIVN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.